S&P 500   3,901.82 (+2.38%)
DOW   31,535.51 (+1.95%)
QQQ   323.59 (+3.01%)
AAPL   127.79 (+5.39%)
MSFT   236.94 (+1.96%)
FB   264.91 (+2.83%)
GOOGL   2,069.66 (+2.36%)
TSLA   718.43 (+6.36%)
AMZN   3,146.14 (+1.72%)
NVDA   553.67 (+0.93%)
BABA   241.69 (+1.65%)
CGC   34.73 (+6.05%)
GE   13.11 (+4.55%)
MU   94.76 (+3.53%)
NIO   49.76 (+8.69%)
AMD   86.39 (+2.22%)
T   28.09 (+0.72%)
F   11.98 (+2.39%)
ACB   11.04 (+4.94%)
DIS   194.98 (+3.14%)
BA   224.39 (+5.84%)
NFLX   550.64 (+2.19%)
BAC   35.79 (+3.11%)
S&P 500   3,901.82 (+2.38%)
DOW   31,535.51 (+1.95%)
QQQ   323.59 (+3.01%)
AAPL   127.79 (+5.39%)
MSFT   236.94 (+1.96%)
FB   264.91 (+2.83%)
GOOGL   2,069.66 (+2.36%)
TSLA   718.43 (+6.36%)
AMZN   3,146.14 (+1.72%)
NVDA   553.67 (+0.93%)
BABA   241.69 (+1.65%)
CGC   34.73 (+6.05%)
GE   13.11 (+4.55%)
MU   94.76 (+3.53%)
NIO   49.76 (+8.69%)
AMD   86.39 (+2.22%)
T   28.09 (+0.72%)
F   11.98 (+2.39%)
ACB   11.04 (+4.94%)
DIS   194.98 (+3.14%)
BA   224.39 (+5.84%)
NFLX   550.64 (+2.19%)
BAC   35.79 (+3.11%)
S&P 500   3,901.82 (+2.38%)
DOW   31,535.51 (+1.95%)
QQQ   323.59 (+3.01%)
AAPL   127.79 (+5.39%)
MSFT   236.94 (+1.96%)
FB   264.91 (+2.83%)
GOOGL   2,069.66 (+2.36%)
TSLA   718.43 (+6.36%)
AMZN   3,146.14 (+1.72%)
NVDA   553.67 (+0.93%)
BABA   241.69 (+1.65%)
CGC   34.73 (+6.05%)
GE   13.11 (+4.55%)
MU   94.76 (+3.53%)
NIO   49.76 (+8.69%)
AMD   86.39 (+2.22%)
T   28.09 (+0.72%)
F   11.98 (+2.39%)
ACB   11.04 (+4.94%)
DIS   194.98 (+3.14%)
BA   224.39 (+5.84%)
NFLX   550.64 (+2.19%)
BAC   35.79 (+3.11%)
S&P 500   3,901.82 (+2.38%)
DOW   31,535.51 (+1.95%)
QQQ   323.59 (+3.01%)
AAPL   127.79 (+5.39%)
MSFT   236.94 (+1.96%)
FB   264.91 (+2.83%)
GOOGL   2,069.66 (+2.36%)
TSLA   718.43 (+6.36%)
AMZN   3,146.14 (+1.72%)
NVDA   553.67 (+0.93%)
BABA   241.69 (+1.65%)
CGC   34.73 (+6.05%)
GE   13.11 (+4.55%)
MU   94.76 (+3.53%)
NIO   49.76 (+8.69%)
AMD   86.39 (+2.22%)
T   28.09 (+0.72%)
F   11.98 (+2.39%)
ACB   11.04 (+4.94%)
DIS   194.98 (+3.14%)
BA   224.39 (+5.84%)
NFLX   550.64 (+2.19%)
BAC   35.79 (+3.11%)
Log in
NASDAQ:ATHE

Alterity Therapeutics Stock Forecast, Price & News

$1.69
+0.09 (+5.63 %)
(As of 03/1/2021 05:20 PM ET)
Add
Compare
Today's Range
$1.60
Now: $1.69
$1.71
50-Day Range
$1.52
MA: $1.80
$2.18
52-Week Range
$0.28
Now: $1.69
$5.15
Volume242,651 shs
Average Volume937,106 shs
Market Capitalization$38.20 million
P/E RatioN/A
Dividend YieldN/A
Beta1.63
Alterity Therapeutics Limited researches and develops therapeutic drugs for the treatment of Parkinsonian's disease and other neurodegenerative diseases in Australia. The company's lead drug candidates is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 for used as an antimicrobial agent. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. The company was founded in 1997 and is based in Melbourne, Australia.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ATHE
CUSIPN/A
CIKN/A
Phone61 3 9349 4906
Employees12
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$90,000.00
Book Value$0.33 per share

Profitability

Miscellaneous

Market Cap$38.20 million
Next Earnings DateN/A
OptionableNot Optionable

MarketRank

Overall MarketRank

0.17 out of 5 stars

Medical Sector

1761st out of 1,965 stocks

Pharmaceutical Preparations Industry

720th out of 772 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
$1.69
+0.09 (+5.63 %)
(As of 03/1/2021 05:20 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ATHE News and Ratings via Email

Sign-up to receive the latest news and ratings for ATHE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Alterity Therapeutics (NASDAQ:ATHE) Frequently Asked Questions

What stocks does MarketBeat like better than Alterity Therapeutics?

Wall Street analysts have given Alterity Therapeutics a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Alterity Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Alterity Therapeutics?

Alterity Therapeutics saw a increase in short interest during the month of February. As of February 12th, there was short interest totaling 98,700 shares, an increase of 961.3% from the January 28th total of 9,300 shares. Based on an average daily trading volume, of 765,600 shares, the short-interest ratio is presently 0.1 days.
View Alterity Therapeutics' Short Interest
.

Who are Alterity Therapeutics' key executives?

Alterity Therapeutics' management team includes the following people:
  • Mr. Geoffrey Paul Kempler B.Sc., B.Sc, Co-Founder & Non-Exec. Chairman (Age 66)
  • Dr. David A. Stamler, CEO, Chief Medical Officer & Sr. VP of Clinical Devel. (Age 60)
  • Ms. Kathryn J. E. Andrews, Chief Financial Officer (Age 54)
  • Dr. Rudolph Emile Tanzi, Chief Scientific Advisor and Member of R&D Advisory Board
  • Dr. Steven D. Targum, Chief Medical Advisor
  • Dr. Robert Cherny, Head of Research
  • Mr. Phillip Allen Hains, Company Sec. (Age 62)

Who are some of Alterity Therapeutics' key competitors?

What other stocks do shareholders of Alterity Therapeutics own?

What is Alterity Therapeutics' stock symbol?

Alterity Therapeutics trades on the NASDAQ under the ticker symbol "ATHE."

Who are Alterity Therapeutics' major shareholders?

Alterity Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (1.42%).

Which institutional investors are buying Alterity Therapeutics stock?

ATHE stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC.

How do I buy shares of Alterity Therapeutics?

Shares of ATHE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Alterity Therapeutics' stock price today?

One share of ATHE stock can currently be purchased for approximately $1.71.

How much money does Alterity Therapeutics make?

Alterity Therapeutics has a market capitalization of $38.65 million and generates $90,000.00 in revenue each year.

How many employees does Alterity Therapeutics have?

Alterity Therapeutics employs 12 workers across the globe.

What is Alterity Therapeutics' official website?

The official website for Alterity Therapeutics is www.alteritytherapeutics.com.

Where are Alterity Therapeutics' headquarters?

Alterity Therapeutics is headquartered at LEVEL 3 460 BOURKE STREET, MELBOURNE C3, VIC 3000.

How can I contact Alterity Therapeutics?

Alterity Therapeutics' mailing address is LEVEL 3 460 BOURKE STREET, MELBOURNE C3, VIC 3000. The company can be reached via phone at 61 3 9349 4906 or via email at [email protected]


This page was last updated on 3/1/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.